APOA1 and autoimmune disease: Anti-apoA-I IgG is thus recognised as an independent predictor of poor cardiovascular outcome in several different populations at risk for CVD with and without concomitant autoimmune disease and provides incremental prognostic information over traditional risk factors for CVD [20].